公开(公告)号：KR1020130017794A

公开(公告)日：2013-02-20

申请号：KR1020110080434

申请日：2011-08-12

Applicant: 전남대학교병원

Inventor： 엄광현 ,  기해진 ,  국현

IPC: A61K31/37 ,  A61K31/351 ,  A61K31/4192 ,  A61P9/00

Abstract: PURPOSE: A composition containing an expression or activation inhibitor of casein phosphorylase 2(CK2) protein is provided to treat or prevent cardiomegaly or cardiac insufficiency. CONSTITUTION: A composition for suppressing cardiomegaly contains an expression or activation inhibitor of CK2 protein as an active ingredient. The inhibitor suppresses phosphorylation by being conjugated at a serine site of histone deacetylase(HDAC2) protein. The inhibitor is CK2α1 siRNA(short interfering RNA) or a gene which transcribes the same. The inhibitor is apigenin of chemical formula 1, TBB(4,5,6,7-tetrabromobenzotriazole) of chemical formula 2, or TBCA((E)-3-(2,3,4,5-tetrabromophenyl) acrylic acid) of chemical formula 3.

Abstract translation: 目的：提供含有酪蛋白磷酸化酶2（CK2）蛋白表达或活化抑制剂的组合物，用于治疗或预防心脏肥大或心脏功能不全。 构成：用于抑制心脏肥大的组合物含有CK2蛋白的表达或活化抑制剂作为活性成分。 抑制剂通过在组蛋白脱乙酰酶（HDAC2）蛋白的丝氨酸位点缀合而抑制磷酸化。 抑制剂是CK2α1siRNA（短干扰RNA）或其转录的基因。 抑制剂是化学式1的芹菜素，化学式2的TBB（4,5,6,7-四溴苯并三唑）或TBCA（（E）-3-（2,3,4,5-四溴苯基）丙烯酸） 化学式3。

公开(公告)号：KR101264650B1

公开(公告)日：2013-05-15

申请号：KR1020110080434

申请日：2011-08-12

Applicant: 전남대학교병원

Inventor： 엄광현 ,  기해진 ,  국현

IPC: A61K31/37 ,  A61K31/351 ,  A61K31/4192 ,  A61P9/00

Abstract: 본발명은카세인인산화효소 2(CK2) 단백질의발현또는작용억제제를유효성분으로포함하는심장비대억제조성물에관한것으로, 보다상세하게는아피제닌(apigenin), TBB(4,5,6,7-tetrabromobenzotriazole, TBB) 및 TBCA((E)-3-(2,3,4,5-tetrabromophenyl) acrylic acid)로선택되는하나이상의것을특징으로하는심장비대억제조성물에관한것이다. 상기조성물은심장비대증또는심부전증으로구성된군에서선택된어느하나의질병치료또는예방용인약학조성물에관한것으로, 복강내로투여용인것을특징으로한다.

公开(公告)号：KR1020120114501A

公开(公告)日：2012-10-17

申请号：KR1020110032046

申请日：2011-04-07

Applicant: 전남대학교병원

Inventor： 기해진 ,  권진숙 ,  국현 ,  안영근 ,  정명호

IPC: A61K31/165 ,  A61K31/16 ,  A61P9/10 ,  A61P9/00

Abstract: PURPOSE: A composition for restenosia prevention and a medicine for arteriosclerosis including the same are provided to prevent restenosia inside a stent and to minimize a side effect in which tunica intima of the blood vessel endothelial cell is slowly re-progressed after the stent treatment. CONSTITUTION: A composition for restenosia prevention includes trichostatin A(TSA) represented as chemical formula 1. The active ingredient prevents the formation of vascularization tunica intima or suppression of vascular smooth muscle cells. The composition is coated on the stent or balloon and is injected in the artery part and orally or non-orally administered. The composition is directly spread on the artery part in 1-3 mm thickness and is injected. The artery part is atherosclerosis panel site. The medicine for arteriosclerosis includes the composition for preventing restenosis. The medicine is a stent in which the composition is spread on the surface.

Abstract translation: 目的：提供一种用于预防再狭窄的组合物和包括其的用于动脉硬化的药物以防止支架内的再狭窄，并且使支架治疗后血管内皮细胞的内膜缓慢地再次进行的副作用最小化。 构成：预防复发的组合物包括以化学式1表示的曲古抑菌素A（TSA）。活性成分可防止内膜血管形成或血管平滑肌细胞的抑制。 将组合物涂布在支架或球囊上，并注入动脉部分，口服或非口服给药。 将组合物直接铺展在1-3mm厚度的动脉部分上并注射。 动脉部分为动脉粥样硬化斑块。 用于动脉硬化的药物包括用于预防再狭窄的组合物。 药物是组合物在表面上扩散的支架。